Workflow
Contract Research Organizations (CROs)
icon
Search documents
FTRE Investors Have the Opportunity to Lead the Fortrea Holdings Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Prnewswire· 2025-07-08 15:10
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 8, 2025 /PRNewswire/ - ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
GlobeNewswire News Room· 2025-07-06 11:25
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea Holdings Inc. due to allegations of misleading statements and financial misrepresentations that have negatively impacted investors [3][5]. Group 1: Legal Investigation and Claims - Investors who suffered losses exceeding $50,000 in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - A federal securities class action has been filed against Fortrea, with a deadline of August 1, 2025, for investors to seek the role of lead plaintiff [3]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting Transition Services Agreements (TSAs), leading to inflated EBITDA targets for 2025 [5]. - The company's public statements regarding its business model and financial prospects were claimed to be materially false and misleading [5]. Group 3: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the business model and a subsequent stock price drop of $2.73 per share (12.29%) to close at $19.48 [6]. - Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, after the company canceled two scheduled conferences, resulting in a stock price decline of $1.90 per share (8.06%) to close at $21.67 [7]. - Following the announcement of disappointing financial results on March 3, 2025, Fortrea's stock fell by $3.47 per share (25.05%) to close at $10.38, with the company acknowledging that its revenue and EBITDA expectations for 2025 were not met [8].
Fortrea (FTRE) - 2024 FY - Earnings Call Presentation
2025-06-17 12:04
January 10, 2024 Labcorp's Clinical Development and Commercialization Services business is now Fortrea (NASDAQ: FTRE). ©2023 Fortrea Inc. All rights reserved. Confidential. 42nd Annual J.P. Morgan Healthcare Conference Fortrea Tom Pike, Chief Executive Officer & Chairman of the Board Jill McConnell, Chief Financial Officer FORWARD LOOKING STATEMENTS & NON-GAAP FINANCIAL MEASURES Labcorp's Clinical Development and Commercialization Services business is now Fortrea (NASDAQ: FTRE). ©2023 Fortrea Inc. All right ...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea
GlobeNewswire News Room· 2025-06-12 21:44
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fortrea To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings
Prnewswire· 2025-06-10 13:46
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fortrea To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securites in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, ...
Inotiv (NOTV) 2025 Conference Transcript
2025-06-04 20:45
Inotiv (NOTV) 2025 Conference June 04, 2025 03:45 PM ET Speaker0 Okay. Okay. Alright. Hi. Good afternoon. I'm Dave Windley with Jefferies Healthcare Equity Research, CRO coverage. Thanks so much for attending or listening to our twenty twenty five Healthcare Conference here in New York. Our next presenting company is Innative. NOTV is the ticker and the company's CEO is here with us. Bob Leisure, Beth Taylor here in front of me in the audience. The company's CFO is also along with. So Bob, we just said this ...
ICON Public Company (ICLR) FY Conference Transcript
2025-06-04 16:40
ICON Public Company (ICLR) FY Conference June 04, 2025 11:40 AM ET Speaker0 Alright. Good morning, everyone, and thanks for joining us today for the management presentation. My name is Max Mach, and I'm the research analyst here at William Blair who covers Icon. We're pleased to be joined this morning by CEO, doctor Steve Cutler, and Kate Haven, vice president, investor relations. Before we get into the presentation, I have to mention two things. First, the breakout session will be held in Adler on the seco ...
ICLR Shareholders Have the Right to Lead the ICON Public Limited Company Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ICLR
Prnewswire· 2025-06-02 08:12
Core Viewpoint - A class action lawsuit has been filed against ICON Public Limited Company for alleged violations of federal securities laws, specifically regarding misleading statements about its business performance and customer engagements [1] Group 1: Lawsuit Details - The lawsuit pertains to shareholders who purchased ICON's securities between July 27, 2023, and October 23, 2024 [1] - Allegations include that ICON misrepresented its business stability, claiming it did not suffer losses due to customer funding limitations [1] - The company's Functional Service Provision (FSP) and hybrid models were ineffective in mitigating market downturn impacts [1] Group 2: Customer Behavior - Customers reportedly used Requests for Proposals (RFPs) as a pricing tool rather than a genuine demand indicator [1] - There were cancellations of contracts and reductions in engagements as existing agreements concluded [1] - ICON's two largest clients began diversifying their Clinical Research Organization (CRO) providers by incorporating competitors [1]
IQVIA (IQV) 2025 Conference Transcript
2025-05-13 22:20
Summary of IQVIA (IQV) 2025 Conference Call Company Overview - **Company**: IQVIA (IQV) - **Industry**: Life Sciences Tools and Diagnostics Key Financial Highlights - **Q1 Performance**: Revenue exceeded the high end of guidance, EBITDA was above the midpoint, and EPS was at the high end of guidance [3][4] - **TAS Growth**: TAS experienced over 7.6% growth at constant currency [3] - **Cash Flow**: Cash flow increased by 13% year-over-year, representing 89% of adjusted net income, which is at the high end of forecasts [4] - **Revenue Guidance**: Revenue guidance was raised by $275 million, primarily due to foreign exchange (FX) impacts [4] - **Bookings**: Book-to-bill ratio was 1.02, with a noted slowdown in decision-making and an increase in the time between RFPs and awards by about 10% [5][6] Industry Dynamics - **Emerging Biopharma vs. Large Pharma**: Emerging biopharma is experiencing a slowdown in funding, while large pharma is facing delays in decision-making due to uncertainty from recent government actions [8][9] - **Funding Environment**: The funding environment for biotech has been weak year-to-date, impacting order placements and decision-making [10][11] - **Regulatory Environment**: Concerns regarding agency changes, tariffs, and pricing actions are affecting large pharma's decision-making processes [13][14][17] Market Trends - **Real World Evidence (RWE)**: Growth in RWE is driven by the introduction of new drugs and increased scrutiny from payers for evidence of effectiveness [29][32] - **TAS Business**: The TAS segment is expected to continue its recovery, supported by new drug approvals and the need for commercialization support [22][23][26] Competitive Landscape - **Pricing Pressure**: Increased competition has led to pricing pressures, particularly in the FSP business, but management is focused on offsetting this with cost reductions [40][41] - **Market Dynamics**: Smaller CROs are feeling more pressure for business, which may lead to increased pricing competition [42] Margin and Growth Outlook - **Margin Projections**: Adjusted EBITDA margin is projected to contract by 20 basis points due to FX impacts, but long-term margin growth is expected to remain stable [45][49] - **Revenue Growth Expectations**: Anticipated constant currency revenue growth of 6-9% annually, driven by pharma spending, market share expansion, outsourcing, and M&A [49][50] Capital Deployment Strategy - **M&A and Share Repurchase**: The company is focused on M&A and share repurchase, with a preference for M&A opportunities that enhance growth capabilities [51][54] - **Debt Management**: Comfortable with current debt levels, with a net leverage ratio between 3.3 and 3.5 [52] Underappreciated Aspects - **Business Model**: IQVIA is not a pure CRO; its TAS business represents 40% of operations, which is often overlooked in comparisons with CRO peers [57][58] This summary encapsulates the key points discussed during the IQVIA conference call, highlighting the company's financial performance, industry dynamics, market trends, competitive landscape, margin outlook, capital deployment strategy, and aspects of the business that may be underappreciated.
Charles River(CRL) - 2025 Q1 - Earnings Call Transcript
2025-05-07 14:02
Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Todd Spencer - Vice President, Investor RelationsJames Foster - Chairman, President and CEOFlavia Pease - Corporate Executive VP & CFOElizabeth Anderson - Senior Managing DirectorDave Windley - Managing DirectorMichael Ryskin - Managing DirectorKyle Crews - Equity Research AssociatePatrick Donnelly - Managing DirectorCasey Woodring - Vice President - Equity ResearchCharles Rhyee - Managing Dire ...